

Deena M A Gendoo

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1864606/deena-m-a-gendoo-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

13
papers

597
citations

9
h-index

15
g-index

15
ext. papers

854
ext. citations

8.5
avg, IF

3.49
L-index

#	Paper	IF	Citations
13	Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. <i>Bioinformatics</i> , 2016 , 32, 1097-9	7.2	150
12	CD73 is associated with poor prognosis in high-grade serous ovarian cancer. <i>Cancer Research</i> , 2015 , 75, 4494-503	10.1	142
11	PharmacGx: an R package for analysis of large pharmacogenomic datasets. <i>Bioinformatics</i> , 2016 , 32, 1244-6	7.2	127
10	Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma. <i>Clinical Cancer Research</i> , 2018 , 24, 5037-5047	12.9	43
9	Public data and open source tools for multi-assay genomic investigation of disease. <i>Briefings in Bioinformatics</i> , 2016 , 17, 603-15	13.4	38
8	Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. <i>PLoS Computational Biology</i> , 2019 , 15, e1006596	5	29
7	Integrative Cancer Pharmacogenomics to Infer Large-Scale Drug Taxonomy. <i>Cancer Research</i> , 2017 , 77, 3057-3069	10.1	20
6	A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling. <i>Breast Cancer Research</i> , 2019 , 21, 18	8.3	20
5	MetaGxData: Clinically Annotated Breast, Ovarian and Pancreatic Cancer Datasets and their Use in Generating a Multi-Cancer Gene Signature. <i>Scientific Reports</i> , 2019 , 9, 8770	4.9	15
4	Modeling germline mutations in pineoblastoma uncovers lysosome disruption-based therapy. <i>Nature Communications</i> , 2020 , 11, 1825	17.4	7
3	Bioinformatics and computational approaches for analyzing patient-derived disease models in cancer research. <i>Computational and Structural Biotechnology Journal</i> , 2020 , 18, 375-380	6.8	3
2	MM2S: personalized diagnosis of medulloblastoma patients and model systems. <i>Source Code for Biology and Medicine</i> , 2016 , 11, 6	1.9	1
1	The anti-tumour activity of DNA methylation inhibitor 5-aza-2-deoxycytidine is enhanced by the common analgesic paracetamol through induction of oxidative stress. <i>Cancer Letters</i> , 2021 , 501, 172-186 ^{9,9}		1